Patents by Inventor Valeriu Bortnov

Valeriu Bortnov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD TO INHIBIT NEUTROPHIL RECRUITMENT TO DAMAGED TISSUE USING MYELOID-DERIVED GROWTH FACTOR
    Publication number: 20240299494
    Abstract: A method to inhibit neutrophil recruitment to damaged tissue, thereby inhibiting inflammation in a subject. The method includes administering to an anti-inflammatory amount of a myeloid-derived growth factor (“MYDGF”). Also disclosed are corresponding pharmaceutical compositions of matter containing the MYDGF.
    Type: Application
    Filed: April 11, 2024
    Publication date: September 12, 2024
    Applicant: Wisconsin Alumni Research Foundation
    Inventors: Anna Huttenlocher, Deane Mosher, Valeriu Bortnov, David Bennin, Ruth Anne Houseright, Frances M. Smith
  • Method to inhibit neutrophil recruitment to damaged tissue using myeloid-derived growth factor
    Patent number: 11980654
    Abstract: A method to inhibit neutrophil recruitment to damaged tissue, thereby inhibiting inflammation in a subject. The method includes administering to an anti-inflammatory amount of a myeloid-derived growth factor (“MYDGF”). Also disclosed are corresponding pharmaceutical compositions of matter containing the MYDGF.
    Type: Grant
    Filed: September 22, 2021
    Date of Patent: May 14, 2024
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Anna Huttenlocher, Deane Mosher, Valeriu Bortnov, David Bennin, Ruth Anne Houseright, Frances M Smith
  • METHOD TO INHIBIT NEUTROPHIL RECRUITMENT TO DAMAGED TISSUE USING MYELOID-DERIVED GROWTH FACTOR
    Publication number: 20220168390
    Abstract: A method to inhibit neutrophil recruitment to damaged tissue, thereby inhibiting inflammation in a subject. The method includes administering to an anti-inflammatory amount of a myeloid-derived growth factor (“MYDGF”). Also disclosed are corresponding pharmaceutical compositions of matter containing the MYDGF.
    Type: Application
    Filed: September 22, 2021
    Publication date: June 2, 2022
    Inventors: Anna Huttenlocher, Deane Mosher, Valeriu Bortnov, David Bennin